Effect of calcium antagonist gallopamil on antigen-induced early and late bronchoconstrictor responses in allergic sheep

J. D'Brot, W. M. Abraham, T. Ahmed

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Calcium channel blockers have been shown to modify acute antigen-induced bronchoconstriction in allergic animals and in some human subjects with bronchial asthma; however, the effects of calcium antagonists on late-phase bronchial responses are not known. In this investigation, we studied the effects of calcium antagonist gallopamil on antigen-induced early- and late-phase bronchial responses in sheep allergic to Ascaris suum antigen. In 11 unsedated sheep, specific lung resistance (SRL) was measured before, immediately after, and serially up to 8 h after inhalation challenge with A. suum antigen. On different experiment days, at least 3 wk apart, the sheep were pretreated with gallopamil, administered either as an aerosol (5 mg, n = 10; 10 mg, n = 9) or as an intravenous injection (20 μg/kg, n = 10), and the antigen challenge was repeated. For the control experiments (n = 11), mean ± SE SRL increased immediately after antigen challenge (early response) to 533 ± 72% of baseline and again 6 to 8 h after challenge (late response) to 304 ± 31% of baseline (p < 0.05). Neither intravenously administered nor aerosolized gallopamil had a significant effect on baseline SRL. Both aerosolized and intravenously administered gallopamil blunted the early response and completely blocked the late-phase bronchoconstrictor response (p < 0.05). Mean SRL during early phase increased to 208 ± 39% and 245 ± 39% of baseline with 5 mg and 10 mg of aerosolized gallopamil and to 191 ± 35% of baseline with intravenously administered gallopamil, respectively. During the late phase, mean SRL increased to 109 ± 6%, 139 ± 14%, and 126 ± 13% of baseline with aerosol (5 mg and 10 mg) and intravenously administered gallopamil, respectively; these values were not significantly different from their respective baselines. These data suggest that the calcium antagonist gallopamil attenuates early- and late-phase allergic airway responses and thus may be of potential clinical use.

Original languageEnglish
Pages (from-to)915-920
Number of pages6
JournalAmerican Review of Respiratory Disease
Volume139
Issue number4 I
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Bronchoconstrictor Agents
Gallopamil
Sheep
Calcium
Antigens
Ascaris suum
Aerosols
Bronchoconstriction
Calcium Channel Blockers
Intravenous Injections
Inhalation
Asthma
Lung

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Effect of calcium antagonist gallopamil on antigen-induced early and late bronchoconstrictor responses in allergic sheep. / D'Brot, J.; Abraham, W. M.; Ahmed, T.

In: American Review of Respiratory Disease, Vol. 139, No. 4 I, 01.01.1989, p. 915-920.

Research output: Contribution to journalArticle

@article{05e52942e26f45e7bba093f09a5827da,
title = "Effect of calcium antagonist gallopamil on antigen-induced early and late bronchoconstrictor responses in allergic sheep",
abstract = "Calcium channel blockers have been shown to modify acute antigen-induced bronchoconstriction in allergic animals and in some human subjects with bronchial asthma; however, the effects of calcium antagonists on late-phase bronchial responses are not known. In this investigation, we studied the effects of calcium antagonist gallopamil on antigen-induced early- and late-phase bronchial responses in sheep allergic to Ascaris suum antigen. In 11 unsedated sheep, specific lung resistance (SRL) was measured before, immediately after, and serially up to 8 h after inhalation challenge with A. suum antigen. On different experiment days, at least 3 wk apart, the sheep were pretreated with gallopamil, administered either as an aerosol (5 mg, n = 10; 10 mg, n = 9) or as an intravenous injection (20 μg/kg, n = 10), and the antigen challenge was repeated. For the control experiments (n = 11), mean ± SE SRL increased immediately after antigen challenge (early response) to 533 ± 72{\%} of baseline and again 6 to 8 h after challenge (late response) to 304 ± 31{\%} of baseline (p < 0.05). Neither intravenously administered nor aerosolized gallopamil had a significant effect on baseline SRL. Both aerosolized and intravenously administered gallopamil blunted the early response and completely blocked the late-phase bronchoconstrictor response (p < 0.05). Mean SRL during early phase increased to 208 ± 39{\%} and 245 ± 39{\%} of baseline with 5 mg and 10 mg of aerosolized gallopamil and to 191 ± 35{\%} of baseline with intravenously administered gallopamil, respectively. During the late phase, mean SRL increased to 109 ± 6{\%}, 139 ± 14{\%}, and 126 ± 13{\%} of baseline with aerosol (5 mg and 10 mg) and intravenously administered gallopamil, respectively; these values were not significantly different from their respective baselines. These data suggest that the calcium antagonist gallopamil attenuates early- and late-phase allergic airway responses and thus may be of potential clinical use.",
author = "J. D'Brot and Abraham, {W. M.} and T. Ahmed",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "139",
pages = "915--920",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "4 I",

}

TY - JOUR

T1 - Effect of calcium antagonist gallopamil on antigen-induced early and late bronchoconstrictor responses in allergic sheep

AU - D'Brot, J.

AU - Abraham, W. M.

AU - Ahmed, T.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Calcium channel blockers have been shown to modify acute antigen-induced bronchoconstriction in allergic animals and in some human subjects with bronchial asthma; however, the effects of calcium antagonists on late-phase bronchial responses are not known. In this investigation, we studied the effects of calcium antagonist gallopamil on antigen-induced early- and late-phase bronchial responses in sheep allergic to Ascaris suum antigen. In 11 unsedated sheep, specific lung resistance (SRL) was measured before, immediately after, and serially up to 8 h after inhalation challenge with A. suum antigen. On different experiment days, at least 3 wk apart, the sheep were pretreated with gallopamil, administered either as an aerosol (5 mg, n = 10; 10 mg, n = 9) or as an intravenous injection (20 μg/kg, n = 10), and the antigen challenge was repeated. For the control experiments (n = 11), mean ± SE SRL increased immediately after antigen challenge (early response) to 533 ± 72% of baseline and again 6 to 8 h after challenge (late response) to 304 ± 31% of baseline (p < 0.05). Neither intravenously administered nor aerosolized gallopamil had a significant effect on baseline SRL. Both aerosolized and intravenously administered gallopamil blunted the early response and completely blocked the late-phase bronchoconstrictor response (p < 0.05). Mean SRL during early phase increased to 208 ± 39% and 245 ± 39% of baseline with 5 mg and 10 mg of aerosolized gallopamil and to 191 ± 35% of baseline with intravenously administered gallopamil, respectively. During the late phase, mean SRL increased to 109 ± 6%, 139 ± 14%, and 126 ± 13% of baseline with aerosol (5 mg and 10 mg) and intravenously administered gallopamil, respectively; these values were not significantly different from their respective baselines. These data suggest that the calcium antagonist gallopamil attenuates early- and late-phase allergic airway responses and thus may be of potential clinical use.

AB - Calcium channel blockers have been shown to modify acute antigen-induced bronchoconstriction in allergic animals and in some human subjects with bronchial asthma; however, the effects of calcium antagonists on late-phase bronchial responses are not known. In this investigation, we studied the effects of calcium antagonist gallopamil on antigen-induced early- and late-phase bronchial responses in sheep allergic to Ascaris suum antigen. In 11 unsedated sheep, specific lung resistance (SRL) was measured before, immediately after, and serially up to 8 h after inhalation challenge with A. suum antigen. On different experiment days, at least 3 wk apart, the sheep were pretreated with gallopamil, administered either as an aerosol (5 mg, n = 10; 10 mg, n = 9) or as an intravenous injection (20 μg/kg, n = 10), and the antigen challenge was repeated. For the control experiments (n = 11), mean ± SE SRL increased immediately after antigen challenge (early response) to 533 ± 72% of baseline and again 6 to 8 h after challenge (late response) to 304 ± 31% of baseline (p < 0.05). Neither intravenously administered nor aerosolized gallopamil had a significant effect on baseline SRL. Both aerosolized and intravenously administered gallopamil blunted the early response and completely blocked the late-phase bronchoconstrictor response (p < 0.05). Mean SRL during early phase increased to 208 ± 39% and 245 ± 39% of baseline with 5 mg and 10 mg of aerosolized gallopamil and to 191 ± 35% of baseline with intravenously administered gallopamil, respectively. During the late phase, mean SRL increased to 109 ± 6%, 139 ± 14%, and 126 ± 13% of baseline with aerosol (5 mg and 10 mg) and intravenously administered gallopamil, respectively; these values were not significantly different from their respective baselines. These data suggest that the calcium antagonist gallopamil attenuates early- and late-phase allergic airway responses and thus may be of potential clinical use.

UR - http://www.scopus.com/inward/record.url?scp=0024566751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024566751&partnerID=8YFLogxK

M3 - Article

C2 - 2930069

AN - SCOPUS:0024566751

VL - 139

SP - 915

EP - 920

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 4 I

ER -